ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 37 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $50,880 | -25.6% | 52,400 | -33.0% | 0.00% | – |
| Q1 2023 | $68,347 | -13.1% | 78,200 | -5.2% | 0.00% | – |
| Q4 2022 | $78,614 | -39.1% | 82,500 | -29.8% | 0.00% | – |
| Q3 2022 | $129,000 | -5.1% | 117,500 | +4.7% | 0.00% | – |
| Q2 2022 | $136,000 | +0.7% | 112,200 | +78.9% | 0.00% | – |
| Q1 2022 | $135,000 | -28.2% | 62,700 | +296.8% | 0.00% | – |
| Q4 2021 | $188,000 | -26.6% | 15,800 | -4.2% | 0.00% | -100.0% |
| Q3 2021 | $256,000 | – | 16,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
| TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
| Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
| Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
| EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
| HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
| HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |